Inconsistent clinical responses to combination therapies create high R&D failure risks, which are mitigated through standardized computational frameworks for quantifying synergistic drug interactions. These systems automate the evaluation of immune checkpoint inhibitor efficacy to accelerate lead candidate selection.
Internal psychological states and cognitive preferences are difficult to quantify objectively due to high variability and lack of direct measurement standards. Standardizing these metrics allows for reliable predictive modeling of long-term health outcomes.